PROFIL Institut fuer Stoffwechselforschung GmbH

Neuss 39 trials 11 recruiting

39 Registered trials

11 Currently recruiting

Organisation

PROFIL Institut fuer Stoffwechselforschung GmbH

Location

Neuss, Germany

Identifier

ORG-100016387

Address

Hellersbergstrasse 9, Hammfeld, 41460, Germany

Departments

N/A
NA
not applicable

Clinical trials at this site (39)

Search interface

A study to test how insulin NNC0471-0119 works in the body in participants with type 2 diabetes when given by an insulin pump. Ended

2024-520230-29-00 Diabetes mellitus type 2 3 2025-07-01
Phase 1 study assessing the pharmacokinetics of NEX-22A in subjects with T2D Ended

2023-508054-25-01 Type 2 diabetes 3 2025-02-26
A study to test how insulin NNC0471-0119 H works in the body in participants with type 1 diabetes when given by an insulin pump. Ended

2024-513472-18-00 Diabetes mellitus type 1 3 2025-01-23
A Trial Comparing Pharmacokinetics, Safety and Tolerability of Two Subcutaneous Concentrations of Dapiglutide Ended

2024-516901-21-00 Weight management 3 2024-12-23
A research study of a new medicine NNC0363-1063 in healthy participants and participants with type 1 diabetes Ended

2024-511808-17-00 Type 1 diabetes mellitus 1 2024-10-31
CK-0045 proof-of-concept study Ended

2024-514191-41-00 Type 2 diabetes and Obesity 4 2024-09-16
A Phase 2 Parallel Group Study in Adults with Type 2 Diabetes to evaluate Efficacy and Safety of GL0034 Ended

2024-513279-41-00 Type 2 diabetes mellitus 4 2024-09-06
Investigating how CagriSema, semaglutide and cagrilintide regulate insulin effects in the body of people with type 2 diabetes. Ended

2023-509483-20-00 Type 2 diabetes 3 2024-04-26
A research study of a new medicine (NNC0650-0013) in healthy men Ended

2023-506134-79-00 Weight management, Diabetes mellitus type 2; healthy su 1 2024-01-23
A study to assess the pharmacokinetics, and glucodynamics of LY3209590 in participants with type 2 diabetes Ended

2023-508008-39-00 Type 2 Diabetes Mellitus 3 2023-12-05
Investigation of safety, tolerability and pharmacokinetics of multiple doses of NNC0113‑6856 in healthy participants, including a subset of … Ended

2023-503891-26-00 Type 2 diabetes 3 2023-09-29
A Translational Phase 1B, 2-Part Study to Evaluate Pharmacokinetics, Safety and Pharmacodynamics of Treatment with ATX-304 Na Salt Tablets. Ended

2023-505967-36-00 Obesity with prediabetes or type 2 diabetes mellitus 3 2023-09-15
A research study comparing the effect of different dosing conditions on blood levels of semaglutide in a new tablet composition in healthy p… Ended

2023-503949-65-00 Type 2 Diabetes 3 2023-08-07
Bioequivalence study of a proposed biosimilar insulin glargine U300 with Toujeo® Ended

2023-504509-36-00 Type 1 Diabetes Mellitus 2
A Phase I Randomized, Single-center, Double-blind, Two-period Crossover Trial to Evaluate Pharmacodynamics, Pharmacokinetics, Safety, and To… Ended

2024-519646-73-00 Type 2 Diabetes Mellitus 3